Effects of annatto-derived tocotrienol supplementation on osteoporosis induced by testosterone deficiency in rats

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 1247-1259

  Chin, Kok Yong ^a   Ima Nirwana, Soelaiman ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Bone remodeling; Osteoporosis; Testosterone; Tocotrienol

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA TOCOTRIENOL; ANNATTO DERIVED TOCOTRIENOL; BETA3 INTEGRIN; BONE SIALOPROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CATENIN; CATHEPSIN K; MESSENGER RNA; OSTEOCALCIN; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TESTOSTERONE ENANTATE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; ANNATTO; BIOLOGICAL MARKER; CAROTENOID; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PLANT EXTRACT; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOSTEOPOROTIC EFFECT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE QUALITY; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMUR; GENE EXPRESSION PROFILING; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORCHIECTOMY; OSSIFICATION; OSTEOPOROSIS; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RAT; TIBIA; TRABECULAR BONE; TRABECULAR NUMBER; TRABECULAR SEPARATION; TRABECULAR THICKNESS; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANIMAL; BIXACEAE; BLOOD; DIET SUPPLEMENTATION; DRUG EFFECTS; RADIOGRAPHY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; BIOLOGICAL MARKERS; BIXACEAE; BONE DENSITY; BONE REMODELING; CAROTENOIDS; COLLAGEN TYPE I; DIETARY SUPPLEMENTS; FEMUR; MALE; ORCHIECTOMY; OSTEOCALCIN; OSTEOPOROSIS; PEPTIDES; PLANT EXTRACTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; TIBIA; TOCOTRIENOLS; X-RAY MICROTOMOGRAPHY;

EID: 84907352754     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S67016     Document Type: Article

References (31)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733.
2. Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int. 2011;22(9):2439-2448.
3. Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203-209.
4. Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009; 20(5):703-714.
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22(3):465-475.
6. Chin KY, Ima-Nirwana S. Sex steroids and bone health status in men. Int J Endocrinol. 2012;2012:208719.
7. Chin KY, Soelaiman IN, Mohamed IN, Ngah WZ. Serum testosterone, sex hormone-binding globulin and total calcium levels predict the calcaneal speed of sound in men. Clinics (Sao Paulo). 2012;67(8):911-916.
8. Varenna M, Bertoldo F, Monaco MD, Giusti A, Martini G, Rossini M. Safety profile of drugs used in the treatment of osteoporosis: a systematical review of the literature. Reumatismo. 2013;65(4):143-166.
9. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.
10. Chin K-Y, Ima-Nirwana S. Vitamin E as an antiosteoporotic agent via receptor activator of nuclear factor kappa-B ligand signaling disruption: current evidence and other potential research areas. Evid Based Complement Alternat Med. 2012;2012:747020.
11. Chin K-Y, Mo H, Soelaiman I-N. A review of the possible mechanisms of action of tocotrienol -a potential antiosteoporotic agent. Curr Drug Targets. 2013;14(13):1533-1541.
12. Aktifanus AT, Shuid AN, Rashid NHA, et al. Comparison of the effects of tocotrienol and estrogen on the bone markers and dynamic changes in postmenopausal osteoporosis rat model. Asian Journal of Animal and Veterinary Advances. 2012;7(3):225-234.
13. Muhammad N, Luke DA, Shuid AN, Mohamed N, Soelaiman IN. Two different isomers of vitamin e prevent bone loss in postmenopausal osteoporosis rat model. Evid Based Complement Alternat Med. 2012;2012:161527.
14. Soelaiman IN, Ming W, Abu Bakar R, et al. Palm tocotrienol supplementation enhanced bone formation in oestrogen-deficient rats. Int J Endocrinol. 2012;2012:7.
15. Ahmad NS, Khalid BA, Luke DA, Ima Nirwana S. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. Clin Exp Pharmacol Physiol. 2005;32(9):761-770.
16. Hermizi H, Faizah O, Ima-Nirwana S, Ahmad Nazrun S, Norazlina M. Beneficial effects of tocotrienol and tocopherol on bone histomorphometric parameters in Sprague-Dawley male rats after nicotine cessation. Calcif Tissue Int. 2009;84(1):65-74.
17. Ima Nirwana S, Suhaniza S. Effects of tocopherols and tocotrienols on body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. J Med Food. 2004;7(1):45-51.
18. Ima-Nirwana S, Fakhrurazi H. Palm vitamin E protects bone against dexamethasone-induced osteoporosis in male rats. Med J Malaysia. 2002;57(2):133-141.
19. Fujita K, Iwasaki M, Ochi H, et al. Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med. 2012;18(4):589-594.
20. Frega N, Mozzon M, Bocci F. Identification and estimation of tocotrienols in the annatto lipid fraction by gas chromatography-mass spectrometry. J Am Oil Chem Soc. 1998;75(12):1723-1727.
21. Abdul-Majeed S, Mohamed N, Soelaiman I-N. Effects of tocotrienol and lovastatin combination on osteoblast and osteoclast activity in estrogen-deficient osteoporosis. Evid Based Complement Alternat Med. 2012;2012:960742.
22. Pierpaoli E, Viola V, Barucca A, Orlando F, Galli F, Provinciali M. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice. Carcinogenesis. 2013; 34(6):1352-1360.
23. Mehat M, Shuid A, Mohamed N, Muhammad N, Soelaiman I. Beneficial effects of vitamin E isomer supplementation on static and dynamic bone histomorphometry parameters in normal male rats. J Bone Miner Metab. 2010;28(5):503-509.
24. Brooks R, Kalia P, Ireland D, Beeton C, Rushton N. Direct inhibition of osteoclast formation and activity by the vitamin E isomer gamma-tocotrienol. Int J Vitam Nutr Res. 2011;81(6):358-367.
25. Ha H, Lee J-H, Kim H-N, Lee ZH. α-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. Biochem Biophys Res Commun. 2011;406(4):546-551.
26. Hosomi A, Arita M, Sato Y, et al. Affinity for α-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. FEBS Lett. 1997;409(1):105-108.
27. Huang H-Y, Appel LJ. Supplementation of diets with α-tocopherol reduces serum concentrations of γ- and δ-tocopherol in humans. J Nutr. 2003;133(10):3137-3140.
28. Ikeda S, Tohyama T, Yoshimura H, Hamamura K, Abe K, Yamashita K. Dietary α-tocopherol decreases α-tocotrienol but not γ-tocotrienol concentration in rats. J Nutr. 2003;133(2):428-434.
29. Chin KY, Ima-Nirwana S. The effects of alpha-tocopherol on bone: a double-edged sword? Nutrients. 2014;6(4):1424-1441.
30. Jacobs CR. The mechanobiology of cancellous bone structural adaptation. J Rehabil Res Dev. 2000;37(2):209-216.
31. Canales RD, Luo Y, Willey JC, et al. Evaluation of DNA microarray results with quantitative gene expression platforms. Nat Biotechnol. 2006;24(9):1115-1122.